Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
The First Clinical Medical College, Guangdong Medical University, Zhanjiang 524000, China.
Int J Biol Sci. 2022 Jan 9;18(4):1313-1327. doi: 10.7150/ijbs.67892. eCollection 2022.
As the most common subtype of non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL) is characterized by a huge degree of clinical and prognostic heterogeneity. Currently, there is an urgent need for highly specific and sensitive biomarkers to predict the therapeutic response of DLBCL and assess which patients can benefit from systemic chemotherapy to help develop more precise therapeutic regimens for DLBCL. Systems biology (holistic study of diseases) is more comprehensive in quantifying and identifying biomarkers, helps addressing major biological problems, and possesses high accuracy and sensitivity. In this article, we provide an overview of research advances in DLBCL prognostic biomarkers made using the multi-omics approach of genomics, transcriptomics, epigenetics, proteomics, metabonomics, radiomics, and the currently developing single-cell technologies.
弥漫性大 B 细胞淋巴瘤（DLBCL）作为最常见的非霍奇金淋巴瘤亚型，其临床和预后异质性巨大。目前迫切需要高度特异和敏感的生物标志物来预测 DLBCL 的治疗反应，并评估哪些患者可以从系统化疗中获益，以帮助为 DLBCL 制定更精确的治疗方案。系统生物学（疾病的整体研究）在定量和识别生物标志物方面更全面，有助于解决主要的生物学问题，并且具有高精度和高灵敏度。本文综述了利用基因组学、转录组学、表观遗传学、蛋白质组学、代谢组学、放射组学和目前正在发展的单细胞技术的多组学方法研究 DLBCL 预后生物标志物的进展。
